XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells.
XMT-2056 是一种 HER2 靶向 STING 激动剂抗体药物偶联物，通过作用于癌细胞和肿瘤驻留免疫细胞来诱导先天性抗肿瘤免疫反应
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2449
Bukhalid Raghida A, Duvall Jeremy R, Lancaster Kelly, Catcott Kalli C, Malli Cetinbas Naniye, Monnell Travis, Routhier Caitlin, Thomas Joshua D, Bentley Keith W, Collins Scott D, Ditty Elizabeth, Eitas Timothy K, Kelleher Eugene W, Shaw Pamela, Soomer-James Jahna, Ter-Ovanesyan Elena, Xu Ling, Zurita Jeffrey, Toader Dorin, Damelin Marc, Lowinger Timothy B
